





Thanks to biosimilar competition, the number of treatment days with anti- TNF medicines increased x2 from 2013-2023





**E56** billion cumulative savings from the impact of biosimilar competition since 2006, E6 billion in 2024 alone





A growing opportunity for patients with over **110** new biologic medicines opening to biosimilar competition by 2032





A considerable opportunity for European healthcare budget: a £53.5Bn market will open to competition by 2032








By 2030, **1st cell & gene therapies** will open to biosimilar competition



**Biosimilar medicines** opportunity remains largely untapped with only 2% volume share of the accessible market in Europe





Biosimilar medicines represent **4**.**0**/**0** of the **total pharmaceutical spending** in Europe (<€10 billion)





## Biosimilar candidates are under development for 1/3 of biologics losing exclusivity by 2032



